A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period.

NCT Number	NCT07622342
Lead Sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions	Generalized Myasthenia Gravis
Enrollment	60 participants
Start Date	2026-06
Primary Completion	2027-09 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-03